S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
TSE:HLS

HLS Therapeutics Stock Forecast, Price & News

C$14.95
-0.03 (-0.20%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
C$14.72
▼
C$15.01
50-Day Range
C$13.86
▼
C$18.27
52-Week Range
C$13.69
▼
C$21.76
Volume
11,277 shs
Average Volume
16,425 shs
Market Capitalization
C$485.14 million
P/E Ratio
N/A
Dividend Yield
1.34%
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


HLS Therapeutics logo

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.

Headlines

HLS Therapeutics (TSE:HLS) Trading 1.7% Higher
January 11, 2022 |  americanbankingnews.com
T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors
November 30, 2021 |  finance.yahoo.com
HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
November 29, 2021 |  finance.yahoo.com
HLS Therapeutics Announces Q3 Fiscal 2021 Financial Results
November 4, 2021 |  finance.yahoo.com
HLS Therapeutics to Host Q3 2021 Financial Results Conference Call
October 21, 2021 |  finance.yahoo.com
This Pharmaceutical Company Just Got a Major Boost
August 27, 2021 |  msn.com
4 Undervalued Stocks to Buy With Just $500
August 19, 2021 |  msn.com
HLS Enters Agreement With Pfizer For Promotion Of Vascepa In Canada - Quick Facts
August 16, 2021 |  nasdaq.com
HLS Therapeutics Announces Participation at Upcoming Investor Conferences
May 26, 2021 |  finance.yahoo.com
What Kind Of Shareholders Hold The Majority In HLS Therapeutics Inc.'s (TSE:HLS) Shares?
May 19, 2021 |  finance.yahoo.com
ALERT: 1 Pharma Stock for Value Investors With a Significant Margin of Safety
May 17, 2021 |  ca.finance.yahoo.com
Here's What Analysts Are Forecasting For HLS Therapeutics Inc. (TSE:HLS) After Its Annual Results
March 20, 2021 |  finance.yahoo.com
HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results
March 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:HLS
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.hlstherapeutics.com
Phone
647-495-9000
Fax
N/A
Employees
88
Year Founded
N/A

Sales & Book Value

Annual Sales
C$60.80 million
Price / Sales
7.98
Cash Flow
C$0.69 per share
Price / Cash Flow
21.64
Book Value
C$5.08 per share
Price / Book
2.94

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
60.74
Current Ratio
1.54
Quick Ratio
1.13

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
48.23
P/E Growth
N/A

Miscellaneous

Outstanding Shares
32,451,000
Free Float
N/A
Market Cap
C$485.14 million
Optionable
Not Optionable

Company Calendar

Ex-Dividend for 12/15 Dividend
10/28/2021
Last Earnings
11/04/2021
Dividend Payable
12/15/2021
Today
1/21/2022
Ex-Dividend for 3/15 Dividend
1/27/2022
Dividend Payable
3/15/2022
Next Earnings (Estimated)
3/17/2022

MarketRank™

Overall MarketRank™

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












HLS Therapeutics (TSE:HLS) Frequently Asked Questions

Is HLS Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLS Therapeutics stock.
View analyst ratings for HLS Therapeutics or view top-rated stocks.

How has HLS Therapeutics' stock price been impacted by COVID-19?

HLS Therapeutics' stock was trading at C$18.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HLS stock has decreased by 20.3% and is now trading at C$14.95.
View which stocks have been most impacted by COVID-19.

When is HLS Therapeutics' next earnings date?

HLS Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for HLS Therapeutics.

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) issued its earnings results on Thursday, November, 4th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.07. The company earned $18.96 million during the quarter, compared to analysts' expectations of $19.56 million.
View HLS Therapeutics' earnings history.

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?

HLS Therapeutics declared a quarterly dividend on Wednesday, November 3rd. Investors of record on Friday, January 28th will be given a dividend of 0.05 per share on Tuesday, March 15th. This represents a $0.20 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Thursday, January 27th.
View HLS Therapeutics' dividend history.

Is HLS Therapeutics a good dividend stock?

HLS Therapeutics pays an annual dividend of C$0.16 per share and currently has a dividend yield of 1.34%.
View HLS Therapeutics' dividend history.

What price target have analysts set for HLS?

4 analysts have issued twelve-month price targets for HLS Therapeutics' shares. Their forecasts range from C$26.00 to C$36.00. On average, they expect HLS Therapeutics' share price to reach C$31.33 in the next year. This suggests a possible upside of 109.6% from the stock's current price.
View analysts' price targets for HLS Therapeutics or view top-rated stocks among Wall Street analysts.

Who are HLS Therapeutics' key executives?

HLS Therapeutics' management team includes the following people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 60, Pay $587.15k)
  • Mr. Gilbert Godin, Co-Founder, Pres, CEO & Director (Age 62, Pay $800.32k)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder & Director (Age 64, Pay $1.93M)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 49, Pay $356.14k)
  • Mr. Sanjiv Sharma, Chief Commercial Officer (Age 65, Pay $460.14k)
  • Dr. Hemanth Jacob Varghese, Sr. VP of Strategy & Operations (Age 45, Pay $382.25k)
  • Mr. Ryan C. Lennox B.A., J.D., Sr. Vice-Pres of Legal, HR & Compliance and Corp. Sec. (Age 40)
  • Ms. Patricia Perry, Vice-Pres Human Resource
  • David Spence, Corp. Controller (Age 53)

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS).

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS."

How do I buy shares of HLS Therapeutics?

Shares of HLS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is HLS Therapeutics' stock price today?

One share of HLS stock can currently be purchased for approximately C$14.95.

How much money does HLS Therapeutics make?

HLS Therapeutics has a market capitalization of C$485.14 million and generates C$60.80 million in revenue each year.

How many employees does HLS Therapeutics have?

HLS Therapeutics employs 88 workers across the globe.

What is HLS Therapeutics' official website?

The official website for HLS Therapeutics is www.hlstherapeutics.com.

How can I contact HLS Therapeutics?

The company can be reached via phone at 647-495-9000.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.